Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 275

1.

Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer.

Rose A, Xu Y, Chen Z, Fan Z, Stamey TA, McNeal JE, Caldwell M, Peehl DM.

Cancer Lett. 2005 Sep 28;227(2):213-22.

PMID:
16112424
3.

Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types.

Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K.

Mol Cancer Res. 2004 Sep;2(9):489-94.

4.

The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J.

J Urol. 2004 Oct;172(4 Pt 1):1297-301.

PMID:
15371827
5.

Elevated expression of inhibin alpha in prostate cancer.

Risbridger GP, Shibata A, Ferguson KL, Stamey TA, McNeal JE, Peehl DM.

J Urol. 2004 Jan;171(1):192-6.

PMID:
14665874
6.

Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.

Naya Y, Fritsche HA, Cheli CD, Stamey TA, Bartsch G, Brawer MK, Childs S, Taneja SS, Lepor H, Partin AW, Sokoll LJ, Chan DW, Babaian RJ.

Urology. 2003 Dec;62(6):1058-62.

PMID:
14665355
7.

Genetic profiling of Gleason grade 4/5 prostate cancer: which is the best prostatic control tissue?

Stamey TA, Caldwell MC, Fan Z, Zhang Z, McNeal JE, Nolley R, Chen Z, Mahadevappa M, Warrington JA.

J Urol. 2003 Dec;170(6 Pt 1):2263-8.

PMID:
14634393
8.
9.

More information on prostate specific antigen and prostate cancer.

Stamey TA.

J Urol. 2003 Aug;170(2 Pt 1):457-8. No abstract available.

PMID:
12853798
10.

Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.

Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, Zhang Z, Warrington JA, Stamey TA.

J Urol. 2003 Apr;169(4):1316-9.

PMID:
12629351
11.

Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression.

Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM.

Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):23-7.

12.

Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?

Naya Y, Stamey TA, Cheli CD, Partin AW, Sokoll LJ, Chan DW, Brawer MK, Taneja SS, Lepor H, Bartsch G, Childs S, Fritsche HA, Babaian RJ.

Urology. 2002 Oct;60(4 Suppl 1):36-41.

PMID:
12384161
13.

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.

Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Bartsch G.

Urology. 2002 Oct;60(4 Suppl 1):31-5.

PMID:
12384160
14.

Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.

Taneja SS, Hsu EI, Cheli CD, Walden P, Bartsch G, Horninger W, Babaian RJ, Fritsche HA, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Lepor H.

Urology. 2002 Oct;60(4 Suppl 1):10-7.

PMID:
12384157
15.

Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis.

Shibata A, Garcia MI, Cheng I, Stamey TA, McNeal JE, Brooks JD, Henderson S, Yemoto CE, Peehl DM.

Prostate. 2002 Sep 1;52(4):269-78.

PMID:
12210487
16.

Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens.

Wise AM, Stamey TA, McNeal JE, Clayton JL.

Urology. 2002 Aug;60(2):264-9.

PMID:
12137824
17.

Re: Pathologic features of prostate cancer found at population-based screening with a four-year interval.

Stamey TA.

J Natl Cancer Inst. 2002 Feb 6;94(3):227-9. No abstract available.

PMID:
11830613
19.

Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.

Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R, Zhang Z.

J Urol. 2001 Dec;166(6):2171-7.

PMID:
11696729
20.

Genetic polymorphisms in the androgen receptor and type II 5 alpha-reductase genes in prostate enlargement.

Shibata A, Stamey TA, McNeal JE, Cheng I, Peehl DM.

J Urol. 2001 Oct;166(4):1560-4.

PMID:
11547131
21.

Perspectives on prostate cancer diagnosis and treatment: a roundtable.

Brawer MK, Stamey TA, Fowler J, Droller M, Messing E, Fair WR.

Urology. 2001 Aug;58(2):135-40.

PMID:
11489681
23.

Secondary cancers in the prostate do not determine PSA biochemical failure in untreated men undergoing radical retropubic prostatectomy.

Stamey TA, McNeal JM, Wise AM, Clayton JL.

Eur Urol. 2001 Apr;39 Suppl 4:22-3. No abstract available.

PMID:
11340281
25.
26.

Assessment of morphometric measurements of prostate carcinoma volume.

Noguchi M, Stamey TA, McNeal JE, Yemoto CE.

Cancer. 2000 Sep 1;89(5):1056-64.

PMID:
10964336
27.

Modified extrafascial radical retropubic prostatectomy technique decreases frequency of positive surgical margins in T2 cancers <2 cm(3).

Villers A, Stamey TA, Yemoto C, Rischmann P, McNeal JE.

Eur Urol. 2000 Jul;38(1):64-73.

PMID:
10859444
28.

An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.

Noguchi M, Stamey TA, Neal JE, Yemoto CE.

J Urol. 2000 Jun;163(6):1751-5.

PMID:
10799175
29.

Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.

Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM.

J Urol. 2000 Apr;163(4):1155-60.

PMID:
10737486
31.
32.

Biological determinants of cancer progression in men with prostate cancer.

Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM.

JAMA. 1999 Apr 21;281(15):1395-400.

PMID:
10217055
33.

Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant.

Bassler TJ Jr, Orozco R, Bassler IC, O'Dowd GJ, Stamey TA.

Urology. 1998 Dec;52(6):1064-9. Review.

PMID:
9836555
34.
35.

Reference material for PSA: the IFCC standardization study. International Federation of Clinical Chemistry.

Stamey TA, Chen Z, Prestigiacomo AF.

Clin Biochem. 1998 Aug;31(6):475-81. No abstract available.

PMID:
9740969
36.
37.

Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.

Eulau SM, Tate DJ, Stamey TA, Bagshaw MA, Hancock SL.

Int J Radiat Oncol Biol Phys. 1998 Jul 1;41(4):735-40.

PMID:
9652832
39.
41.

The male bulbourethral sling procedure for post-radical prostatectomy incontinence.

Schaeffer AJ, Clemens JQ, Ferrari M, Stamey TA.

J Urol. 1998 May;159(5):1510-5. Erratum in: J Urol 1998 Jul;160(1):136.

PMID:
9554344
42.
43.

Serum levels of prostate-specific antigen among Japanese-American and native Japanese men.

Shibata A, Whittemore AS, Imai K, Kolonel LN, Wu AH, John EM, Stamey TA, Paffenbarger RS.

J Natl Cancer Inst. 1997 Nov 19;89(22):1716-20.

PMID:
9390541
44.
46.

Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.

Chen Z, Chen H, Stamey TA.

J Urol. 1997 Jun;157(6):2166-70.

PMID:
9146608
48.

Progress in standardization of immunoassays for prostate-specific antigen.

Stamey TA.

Urol Clin North Am. 1997 May;24(2):269-73.

PMID:
9126223
49.
50.

Some comments on progress in the standardization of immunoassays for prostate-specific antigen.

Stamey TA.

Br J Urol. 1997 Mar;79 Suppl 1:49-52. Review. No abstract available.

PMID:
9088273

Supplemental Content

Loading ...
Support Center